Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN2 | P17655 | 12/20 | 0.54 |
| ▸ | MMP2 | P08253 | 3/20 | 0.41 |
| ▸ | MMP7 | P09237 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931593 | 0.97 | CAPN2 (0.57) | CAPN2MMP2MMP7MMP3MMP1 | |
| SCHEMBL931650 | 0.91 | CAPN2 (0.52) | CAPN2 | |
| SCHEMBL930920 | 0.89 | CAPN2 (0.60) | CAPN2 | |
| SCHEMBL929429 | 0.88 | CAPN2 (0.60) | CAPN2MMP2MMP7MMP9MMP3 | |
| SCHEMBL12943113 | 0.87 | CAPN2 (0.51) | CAPN2MMP2MMP7MMP9MMP3 | |
| SCHEMBL930514 | 0.86 | CAPN2 (0.45) | CAPN2 | |
| SCHEMBL930513 | 0.86 | CAPN2 (0.45) | CAPN2 | |
| SCHEMBL931655 | 0.85 | CAPN2 (0.60) | CAPN2MMP2MMP7MMP9MMP3 | |
| SCHEMBL931580 | 0.85 | CAPN2 (0.61) | CAPN2MMP2MMP7MMP3MMP1 | |
| SCHEMBL12943095 | 0.84 | CAPN2 (0.53) | CAPN2MMP2MMP7MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434762-B2 | Macrocyclic cysteine protease inhibitors and compositions thereof | UNIVERSITY OF CANTERBURY (NZ) | 2016-09-06 | — | — | US | disclosed |
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | LINCOLN UNIVERSITY (NZ) | 2014-07-10 | — | — | US | disclosed |
| US-8710178-B2 | Macrocyclic cysteine protease inhibitors and compositions thereof | LINCOLN UNIVERSITY (NZ) | 2014-04-29 | — | — | US | disclosed |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | UNIVERSITY OF CANTERBURY (NZ) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | CAPN2 4/4885MMP2 164/4885MMP7 250/4885 |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | CAPN2 4/4885MMP2 164/4885MMP7 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.